The Microrna (Mirna) Market is expected to grow at a CAGR of 23.31% to reach USD 3186.2 million by 2028. The miRNA market is experiencing significant growth due to an increasing number of strategic partnerships and collaborations between vendors and key industry players. These alliances are essential for improving distribution channels and enhancing product offerings. For instance, in March 2023, QIAGEN formed a partnership with Les Laboratoires Servier to develop companion diagnostics for acute myeloid leukemia (AML) therapy drugs. Similarly, Regulus Therapeutics, a leading miRNA-based biopharmaceutical company, collaborated with Harvard's Brigham and Women's Hospital in June 2023, announcing progress on preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of amyotrophic lateral sclerosis. These collaborations underscore the market's potential for innovation and growth during the forecast period.
North America dominates the regional market because of The Mirna market refers to the growing business sector centered around microRNAs (mirNAs), small non-coding RNA molecules that play a crucial role in gene expression regulation. This market encompasses research, development, production, and commercialization of mirNAs for therapeutic, diagnostic, and research applications. Companies are investing heavily in this sector due to its potential to revolutionize healthcare and agriculture industries. The global mirNA market is projected to reach significant growth in the coming years, driven by increasing research funding, technological advancements, and regulatory approvals.
There are various factors that drive the Microrna (Mirna) Market market which are as following: In the healthcare industry, the prevalence of neurological disorders, such as Alzheimer's disease, epilepsy, stroke, Parkinson's disease, and brain tumors, is experiencing a significant upward trend due to various contributing factors. These factors include bacterial and viral infections, genetic predispositions, and insufficient immune responses. Neurological disorders are particularly prevalent among individuals with diabetes mellitus, obesity, hypertension, and smoking addictions, whose numbers are also on the rise. Among these neurological conditions, Parkinson's disease is a common affliction that affects a growing percentage of the global population, particularly those aged 60 to 80 years, according to the Centers for Disease Control and Prevention (CDC). The CDC reports that the prevalence of Parkinson's disease increases from 1% to 4% in this age group. The microRNA (mirNA) market holds immense potential for addressing the unmet medical needs of neurological disorder patients by providing innovative therapeutic solutions.
Be the first one to get the industry updates. Request for a sample report
Microrna (Mirna) Market Segmentation
Type (Consumables, Instruments) End-user (Academic and government research institutes, Biotechnology and pharmaceutical companies, CROs and clinical diagnostic centers) Geography (North America, Europe, Asia, Rest of World (ROW))
The market witnesses several challenges, which are as follows In the miRNA market, a significant obstacle for vendors arises from the absence of a standardized approach for miRNA quantification. Numerous investigations have suggested the potential of miRNAs as diagnostic markers for conditions such as acute coronary syndrome, coronary artery disease, heart failure, and various cardiovascular diseases (CVDs). However, research reveals the inconsistencies in methodologies employed by different research groups, which can be attributed to factors like age, sex, and ethnicity, among others. Additionally, technical discrepancies resulting from distinct miRNA isolation protocols can lead to the preferential isolation of extracellular vesicles (EVs), platelets, and protein complexes. These variations ultimately impact the relative concentrations of circulating miRNAs, hindering the reproducibility of research findings.
Stay ahead of your competitors. Download the Free PDF report
Some of the key companies that have been profiled in the report include:
The microRNA (Mirna) market falls under the broader global pharmaceuticals sector, encompassing entities involved in research and development (R&D) or manufacturing of various pharmaceutical offerings, including generic and non-generic drugs, as well as veterinary medicines. According to Technavio, the healthcare industry's overall size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Key growth drivers for the pharmaceuticals market include the increasing aging population: by 2050, approximately one-quarter of the US population and Europe's population ratio are predicted to surpass 60 years old. - The Microrna (Mirna) Market is experiencing significant growth, fueled by the Increasing prevalence of neurological disorders. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
The microRNA (miRNA) market is experiencing significant growth due to the increasing demand for standardized protocols and high-quality samples in clinical studies and research. Non-invasive methods, such as liquid biopsies, are gaining popularity for miRNA isolation and purification, making it possible to diagnose various diseases without the need for invasive procedures. Microarrays and next-generation sequencing are essential research tools for miRNA analysis, enabling the identification of miRNAs associated with oncogenes and tumor suppressor genes in cancer, neurological disorders, cardiovascular diseases, and acute kidney injury. Real-time PCR and diagnostic kits are crucial for molecular diagnostics, providing accurate and reliable results for disease diagnostics. The market for miRNAs is expanding beyond disease diagnostics to include vaccine development and precision medicine. Biomarkers derived from miRNAs have the potential to revolutionize gene regulation studies, leading to new therapeutic approaches for chronic disorders. Healthcare facilities require kits and reagents, instruments, and diagnostic tools to support miRNA research and clinical applications. The market for miRNAs is expected to continue growing as genomic technologies advance and the potential applications expand.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
